<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1006</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>7514676</PubmedId>
            <Abstract>The reverse genetics system has made it possible to modify the influenza virus genome. By this method, we were able to assess influenza virus as a vaccine vector for protecting BALB/c mice against otherwise lethal lymphocytic choriomeningitis virus (LCMV) infection. A single dose of influenza virus [A/WSN/33 (H1N1)] bearing a cytotoxic T-lymphocyte-specific epitope of the LCMV nucleoprotein (residues 116 to 127) in the neuraminidase stalk protected mice against LCMV challenge for at least 4 months. The immunity was mediated by cytotoxic T lymphocytes and was haplotype specific, indicating that the observed protective response was solely a consequence of prior priming with the H-2d LCMV nucleoprotein epitope expressed in the recombinant influenza virus. We also found that as many as 58 amino acids could be inserted into the neuraminidase stalk without loss of viral function. These findings demonstrate the potential of influenza virus as a vaccine vector, with the neuraminidase stalk as a repository for foreign epitopes.</Abstract>
            <ArticleYear>1994</ArticleYear>
            <ArticlePages>3486-90</ArticlePages>
            <ArticleTitle>Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Castrucci</LastName>
                    <ForeName>M R</ForeName>
                </Author>
                <Author>
                    <LastName>Hou</LastName>
                    <ForeName>S</ForeName>
                </Author>
                <Author>
                    <LastName>Doherty</LastName>
                    <ForeName>P C</ForeName>
                </Author>
                <Author>
                    <LastName>Kawaoka</LastName>
                    <ForeName>Y</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101.</Affiliations>
            <ArticleChemicalList>Epitopes;Viral Vaccines;Neuraminidase</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Epitopes(genetics); Female; Genetic Vectors; Lymphocytic Choriomeningitis(prevention &amp; control); Lymphocytic choriomeningitis virus(genetics; immunology); Mice; Mice, Inbred BALB C; Molecular Sequence Data; Neuraminidase(genetics; immunology); Orthomyxoviridae(genetics; immunology); Recombination, Genetic; T-Lymphocytes, Cytotoxic(immunology); Vaccination; Viral Vaccines(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>68</Volume>
                <Issue>6</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP 116-127</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SERPQASGVYMG</LinearSequence>
                        <StartingPosition>116</StartingPosition>
                        <EndingPosition>127</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09992.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11623</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>57607</EpitopeId>
                <ReferenceStartingPosition>116</ReferenceStartingPosition>
                <ReferenceEndingPosition>127</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <TCellId>14123</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8 weeks-old</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>167</MhcAlleleId>
                                    <MhcAlleleId>169</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>Mice were primed with LCMV intravenously, and challenged intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The challenge antigen was a recombinant Influenza A virus with the epitope inserted in to the neuraminidase stalk, lengthening it by 12 amino acids.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Bronchial Aveolar Lavage (BAL)</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>169</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 116-127</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SERPQASGVYMG</LinearSequence>
                                        <StartingPosition>116</StartingPosition>
                                        <EndingPosition>127</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>1639</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Target cells were LB15 (H-2&lt;sup&gt;bxd&lt;/sup&gt; [F1]) infected with a LCMV nucleoprotein construct.  A negative response was shown when target were infected with wild-type vaccinia virus.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14093</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8 weeks-old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SERPQASGVYMG</LinearSequence>
                                            <StartingPosition>116</StartingPosition>
                                            <EndingPosition>127</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>NP 116-127</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11320</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Mice were infected with mutant influenza virus intranasally and intraperitoneally and were then challenged intracerebally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed with a recombinant Influenza A virus with a portion of its neuraminidase stalk replaced by the epitope. .</ImmunizationComments>
                        </Immunization>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>127</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Mice immunized with another recombinant Influenza A virus, in which the epitope was inserted into the stalk lengthening it by 12 amino acids, showed similar responses against LCMV challenge.  Age- and sex-matched H-2&lt;sup&gt;d&lt;/sup&gt; BALB/c mice were protected against virus infection, establishing that immunization with the H-2&lt;sup&gt;d&lt;/sup&gt; LCMV nucleoprotein epitope was solely responsible for the prevention of lethal infection.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14091</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8 weeks-old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SERPQASGVYMG</LinearSequence>
                                            <StartingPosition>116</StartingPosition>
                                            <EndingPosition>127</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>NP 116-127</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11320</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Mice were infected with mutant influenza virus intranasally and intraperitoneally and were then challenged intracerebally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed with a recombinant Influenza A virus with a portion of its neuraminidase stalk replaced by the epitope. .</ImmunizationComments>
                        </Immunization>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>127</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Positive protection was shown up to 142 days after priming.  Mice immunized with another recombinant Influenza A virus, in which the epitope was inserted into the stalk lengthening it by 12 amino acids, also showed protection against LCMV challenge.  Age- and sex-matched H-2&lt;sup&gt;b&lt;/sup&gt; B6 mice were susceptible to virus infection, establishing that immunization with the H-2&lt;sup&gt;d&lt;/sup&gt; LCMV nucleoprotein epitope was solely responsible for the prevention of lethal infection.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <TCellId>14094</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8 weeks-old</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>167</MhcAlleleId>
                                    <MhcAlleleId>169</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SERPQASGVYMG</LinearSequence>
                                            <StartingPosition>116</StartingPosition>
                                            <EndingPosition>127</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09992.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>NP 116-127</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11320</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Mice were infected with mutant influenza virus intranasally and were then challenged intracerebally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed with a recombinant Influenza A virus with the epitope inserted in to the neuraminidase stalk, lengthening it by 12 amino acids. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>169</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Nucleoprotein</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Cervical lymph nodes showed strong LCMV-specific CTL lysis activity, with only weak lysis of target cells infected with wild-type vaccinia virus.   A similar, but less apparent,  response was shown with spleen cells.  Target cells were LB15 (H-2&lt;sup&gt;bxd&lt;/sup&gt; [F1]) infected with a LCMV nucleoprotein construct.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

